Magnetic nanoparticle hyperthermia enhancement of cisplatin chemotherapy cancer treatment

Abstract

Purpose The purpose of this study was to examine the therapeutic effect of magnetic nanoparticle hyperthermia (mNPH) combined with systemic cisplatin chemotherapy in a murine mammary adenocarcinoma model (MTGB). Materials and methods An alternating magnetic field (35.8 kA/m at 165 kHz) was used to activate 110 nm hydroxyethyl starch-coated magnetic nanoparticles (mNP) to a thermal dose of 60 min at 43 °C. Intratumoral mNP were delivered at 7.5 mg of Fe/cm3 of tumour (four equal tumour quadrants). Intraperitoneal cisplatin at 5 mg/kg body weight was administered 1 h prior to mNPH. Tumour regrowth delay time was used to assess the treatment efficacy. Results mNP hyperthermia, combined with cisplatin, was 1.7 times more effective than mNP hyperthermia alone and 1.4 times more effective than cisplatin alone (p<0.05). Conclusions Our results demonstrate that mNP hyperthermia can result in a safe and significant therapeutic enhancement for cisplatin cancer therapy.

Magnetic Particle Imaging for Quantitative Evaluation of Tumor Response to Magnetic Hyperthermia Treatment Combined with Chemotherapy Using Cisplatin

“…When the tumor volume reached approximately 100 mm 3 , the mice were divided into control (n ＝2 ), MHT (n ＝2 ), CDDP (n ＝2 ), and MHT＋CDDP groups (n ＝2 ). In the control group, the mice were sacrificed and the tumors were removed 3 days after the tumor volume exceeded 100 mm 3 . In the MHT and MHT＋CDDP groups, the mice were sacrificed and the tumors were removed 3 days after MHT.…”

“…Thus, the above conditions for the AMF, duration of MHT, and injection dose of Resovist ® appear to have been appropriate for the purpose of this study. Petryk et al reported that intraperitoneal administration of CDDP at a dose of 5 mg/kg body weight improved the delivery of MNPs to tumors in C3H mice inoculated intradermally with MTG-B cells 5) and it helped to enhance the therapeutic effect of MHT 3) . Thus, we also injected CDDP into mice intraperitoneally at a single dose of 5 mg/kg body weight according to their protocol.…”

“…Cis-diammine-dichloroplatinum (II) (Cisplatin; CDDP) is a platinum-based chemotherapeutic agent that has been clinically used for cancer treatment 2) . The mechanism of CDDP cytotoxicity is to affect the formation of DNA adducts and to inhibit transcription and replication 3) . This process induces cell apoptosis, necrosis, and other cell-cycle based mechanisms 3,4) .…”

“…The mechanism of CDDP cytotoxicity is to affect the formation of DNA adducts and to inhibit transcription and replication 3) . This process induces cell apoptosis, necrosis, and other cell-cycle based mechanisms 3,4) . It has been reported that a combination of chemotherapy with use of CDDP and hyperthermia produces beneficial results and synergistically enhances the effectiveness of CDDP and hyperthermia 3,5) .…”

“…This process induces cell apoptosis, necrosis, and other cell-cycle based mechanisms 3,4) . It has been reported that a combination of chemotherapy with use of CDDP and hyperthermia produces beneficial results and synergistically enhances the effectiveness of CDDP and hyperthermia 3,5) . Magnetic hyperthermia treatment (MHT) is an attractive cancer treatment, utilizing the temperature rise of MNPs under an alternating magnetic field (AMF).…”